Hodgkin Lymphoma - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 165 pages

Hodgkin Lymphoma - Pipeline Review, H2 2013



Summary



Global Markets Direct’s, 'Hodgkin Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma. Hodgkin Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope


- A snapshot of the global therapeutic scenario for Hodgkin Lymphoma.
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hodgkin Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Hodgkin Lymphoma 10
Hodgkin Lymphoma Therapeutics under Development by Companies 12
Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Hodgkin Lymphoma Therapeutics - Products under Development by Companies 19
Hodgkin Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Hodgkin Lymphoma Therapeutics Development 21
Bristol-Myers Squibb Company 21
Seattle Genetics, Inc. 22
Gamida Cell Ltd. 23
Plexxikon Inc. 24
Novartis AG 25
Cell Therapeutics, Inc. 26
4SC AG 27
Hana Biosciences, Inc. 28
MethylGene Inc 29
Cytokinetics, Inc 30
Spectrum Pharmaceuticals, Inc. 31
Affimed Therapeutics AG 32
Actinium Pharmaceuticals, Inc. 33
Philogen S.p.A. 34
Italfarmaco S.p.A. 35
MAT Biopharma 36
Stemline Therapeutics, Inc. 37
Syndax Pharmaceuticals, Inc. 38
Xencor, Inc. 39
TaiGen Biotechnology Co., Ltd. 40
Johnson and Johnson Pharmaceutical Research and Development, L.L.C. 41
Sigma-Tau Pharmaceuticals, Inc. 42
Coridon Pty Ltd 43
Hodgkin Lymphoma - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 50
StemEx - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
entinostat - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
pacritinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
brentuximab vedotin - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
MDX-1401 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
mocetinostat - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
vinorelbine tartrate - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
panobinostat - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Afinitor - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
resminostat - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
resminostat - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
SL-101 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
pralatrexate - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
XmAb-2513 - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
ciclopirox olamine - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
LMP-Specific Cytotoxic T-Lymphocytes - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
PLX-3397 - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
burixafor - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
givinostat - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
procarbazine hydrochloride - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes - Drug Profile 98
Product Description 98
Mechanism of Action 98
RandD Progress 98
Therapeutic Tumor Infiltrating Lymphocytes - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 100
Product Description 100
Mechanism of Action 100
RandD Progress 100
LMP-400 - Drug Profile 101
Product Description 101
Mechanism of Action 101
RandD Progress 101
LMP-776 - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
radretumab - Drug Profile 103
Product Description 103
Mechanism of Action 103
RandD Progress 103
Iomab-B - Drug Profile 105
Product Description 105
Mechanism of Action 105
RandD Progress 105
Genetically Modified T Cell - Drug Profile 106
Product Description 106
Mechanism of Action 106
RandD Progress 106
Epstein Barr Virus Vaccine - Drug Profile 107
Product Description 107
Mechanism of Action 107
RandD Progress 107
Human Granzyme B Based Immunotoxin - Drug Profile 108
Product Description 108
Mechanism of Action 108
RandD Progress 108
Hodgkin Lymphoma Therapeutics - Drug Profile Updates 109
Hodgkin Lymphoma Therapeutics - Discontinued Products 147
Hodgkin Lymphoma Therapeutics - Dormant Products 148
Hodgkin Lymphoma - Product Development Milestones 149
Featured News and Press Releases 149
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 149
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 151
Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma 154
Jun 10, 2013: Seattle Genetics Initiates Phase I/II Trial Of Adcetris In Combination With Bendamustine For Hodgkin Lymphoma Patients After Initial Relapse 156
Jun 02, 2013: Seattle Genetics Announces Presentation Of Adcetris Clinical Development Programs At ASCO Annual Meeting 2013 157
Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma 158
May 14, 2013: Seattle Genetics Announces Adcetris Supplemental BLA Accepted For Filing By FDA 159
Mar 22, 2013: Takeda Submits New Drug Application For Brentuximab Vedotin In Japan 160
Mar 18, 2013: Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With Adcetris In Relapsed Hodgkin Lymphoma And Systemic ALCL 161
Feb 01, 2013: Seattle Genetics's Adcetris Obtains Canadian Approval For Treatment Of Hodgkin Lymphoma And Systemic Anaplastic Large Cell Lymphoma 162
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 165
Disclaimer 165

List of Tables

Number of Products Under Development for Hodgkin Lymphoma, H2 2013 10
Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Bristol-Myers Squibb Company, H2 2013 21
Seattle Genetics, Inc., H2 2013 22
Gamida Cell Ltd., H2 2013 23
Plexxikon Inc., H2 2013 24
Novartis AG, H2 2013 25
Cell Therapeutics, Inc., H2 2013 26
4SC AG, H2 2013 27
Hana Biosciences, Inc., H2 2013 28
MethylGene Inc, H2 2013 29
Spectrum Pharmaceuticals, Inc., H2 2013 31
Actinium Pharmaceuticals, Inc., H2 2013 33
Philogen S.p.A., H2 2013 34
Italfarmaco S.p.A., H2 2013 35
Stemline Therapeutics, Inc., H2 2013 37
Syndax Pharmaceuticals, Inc., H2 2013 38
Xencor, Inc., H2 2013 39
TaiGen Biotechnology Co., Ltd., H2 2013 40
Sigma-Tau Pharmaceuticals, Inc., H2 2013 42
Coridon Pty Ltd, H2 2013 43
Assessment by Monotherapy Products, H2 2013 44
Assessment by Stage and Route of Administration, H2 2013 46
Assessment by Stage and Molecule Type, H2 2013 49
Hodgkin Lymphoma Therapeutics - Drug Profile Updates 109
Hodgkin Lymphoma Therapeutics - Discontinued Products 147
Hodgkin Lymphoma Therapeutics - Dormant Products 148

List of Figures

Number of Products under Development for Hodgkin Lymphoma, H2 2013 10
Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 44
Assessment by Route of Administration, H2 2013 45
Assessment by Stage and Route of Administration, H2 2013 46
Assessment by Molecule Type, H2 2013 47
Assessment by Stage and Molecule Type, H2 2013 48

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Pathology Industry: Multiple Sclerosis – Pipeline Review, H1 2012

Pathology Industry: Multiple Sclerosis – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • March 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

Pathology Industry: Non-Small Cell Lung Cancer – Pipeline Review, H1 2012

Pathology Industry: Non-Small Cell Lung Cancer – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • March 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...

Pathology in United States: Breast Cancer – Pipeline Review, H1 2012

Pathology in United States: Breast Cancer – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • March 2014
  • by Global Markets Direct

This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.